S
Sacubitril + Valsartan
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredients: Sacubitril | Valsartan
General information
Subsidy Information and Financing Scheme
[MAF] Sacubitril & Valsartan Tablet, Sacubitril 24 mg + Valsartan 26 mg, Sacubitril 49 mg + Valsartan 51 mg, Sacubitril 97 mg + Valsartan 103 mg
To reduce the risk of cardiovascular death and hospitalisation for heart failure (HF) in patients:
• with chronic HF classified by NYHA Class II-IV symptoms; and
• with left ventricular ejection fraction of 40% or less; and
• who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
• who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.
Drug Guidance for Subsidy
04/01/2022 Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
The Ministry of Health’s Drug Advisory Committee has recommended:
Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients:
with chronic heart failure classified by New York Heart Association (NYHA) Class II - IV symptoms; and
with left ventricular ejection fraction of 40% or less; and
who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.
Sacubitril/valsartan must not be co-administered with an ACE inhibitor or an ARB.
Subsidy status
[R] Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet, Sacubitril 24 mg + Valsartan 26 mg |
|
Tablet, Sacubitril 49 mg + Valsartan 51 mg |
|
Tablet, Sacubitril 97 mg + Valsartan 103 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.